Free Trial

10x Genomics Q1 2023 Earnings Report

10x Genomics logo
$14.04 +0.43 (+3.16%)
(As of 12/20/2024 05:40 PM ET)

10x Genomics EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$0.38

10x Genomics Revenue Results

Actual Revenue
$134.29 million
Expected Revenue
$128.87 million
Beat/Miss
Beat by +$5.42 million
YoY Revenue Growth
+17.30%

10x Genomics Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

AI breakthrough about to upend industry (Ad)

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

10x Genomics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More 10x Genomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 10x Genomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 10x Genomics and other key companies, straight to your email.

About 10x Genomics

10x Genomics (NASDAQ:TXG), a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

View 10x Genomics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings